Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Income from Continuing Operations for 8 consecutive years, with 87174000.0 as the latest value for Q1 2026.

  • Quarterly Income from Continuing Operations fell 54.7% to 87174000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 295280000.0 through Feb 2026, down 41.69% year-over-year, with the annual reading at 264457000.0 for FY2025, 36.62% down from the prior year.
  • Income from Continuing Operations for Q1 2026 was 87174000.0 at Nurix Therapeutics, down from 78221000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 24277000.0 in Q2 2023, with the low at 87174000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 51147529.41, with a median of 45401000.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations soared 46.53% in 2023, then tumbled 83.49% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 46717000.0 in 2022, then rose by 10.19% to 41956000.0 in 2023, then plummeted by 39.55% to 58549000.0 in 2024, then tumbled by 33.6% to 78221000.0 in 2025, then decreased by 11.45% to 87174000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 87174000.0, 78221000.0, and 86421000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.